4/13/21 | Johnson & Johnson Vaccine Update
As of April 13, 2021 UT Health will suspend its administration of the single dose Johnson and Johnson COVID-19 vaccine. This is per CDC and FDA recommendations while they investigate recent reports of rare, but potentially dangerous blood clots that may have been related to the Johnson and Johnson vaccine in certain specific patient populations.
Among 6.8 million doses given, these rare reports have been in six women (out of more than 6.8 million doses) between the ages of 18 to 48 years old, and occurred 6 to 13 days after vaccination. This type of clotting problem has a specific therapy for those in whom it can be identified early. None of the cases of blood clots reported at this time have occurred in Texas, where more than 500,000 doses of the Johnson & Johnson vaccine have been administered.
Those who have received the JNJ vaccine less than two weeks ago, should watch for easy bruising, gum bleeding, nose bleeds, leg or arm pain or swelling, severe headache or abdominal pain, shortness of breath or chest pain. If one of those symptoms is present, they should see a physician.
CDC is convening a meeting of the Advisory Committee on Immunization Practices (ACIP) tomorrow (Wednesday) to review the cases and evaluate their significance.